MedImmune, AstraZeneca’s biologics business, and Inserm Transfert have entered a three-year strategic research collaboration for a range of therapeutic areas including oncology, respiratory, inflammation, and autoimmune diseases. The research will explore translational biology and new disease mechanisms, as well as evaluate potential drug candidates. Financial details were not disclosed. MedImmune will fund the scientific collaboration that will initially investigate 10 research projects, le...